In cholangiocarcinoma, FGFR2 mutations are as high as 20%, and up to 13% of ICCs have fibroblast growth factor receptor 2 (FGFR2) fusion genes (70). This evidence concerns the gene FGFR2 and cholangiocarcinoma.